Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 158

1.

A comprehensive review of lenalidomide therapy for B-cell non-Hodgkin lymphoma.

Witzig TE, Nowakowski GS, Habermann TM, Goy A, Hernandez-Ilizaliturri FJ, Chiappella A, Vitolo U, Fowler N, Czuczman MS.

Ann Oncol. 2015 Feb 23. pii: mdv102. [Epub ahead of print] Review.

PMID:
25712458
[PubMed - as supplied by publisher]
2.

Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.

Frys S, Simons Z, Hu Q, Barth MJ, Gu JJ, Mavis C, Skitzki J, Song L, Czuczman MS, Hernandez-Ilizaliturri FJ.

Br J Haematol. 2015 Feb 23. doi: 10.1111/bjh.13318. [Epub ahead of print]

PMID:
25712263
[PubMed - as supplied by publisher]
3.

Anti-CD22 and anti-CD79B antibody drug conjugates are active in different molecular diffuse large B-cell lymphoma subtypes.

Pfeifer M, Zheng B, Erdmann T, Koeppen H, McCord R, Grau M, Staiger A, Chai A, Sandmann T, Madle H, Dörken B, Chu YW, Chen AI, Lebovic D, Salles GA, Czuczman MS, Palanca-Wessels MC, Press OW, Advani R, Morschhauser F, Cheson BD, Lenz P, Ott G, Polson AG, Mundt KE, Lenz G.

Leukemia. 2015 Feb 24. doi: 10.1038/leu.2015.48. [Epub ahead of print]

PMID:
25708834
[PubMed - as supplied by publisher]
4.

Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma.

Czuczman MS, Kahanic S, Forero A, Davis G, Munteanu M, Van Den Neste E, Offner F, Bron D, Quick D, Fowler N.

Ann Hematol. 2015 Jan 30. [Epub ahead of print]

PMID:
25630297
[PubMed - as supplied by publisher]
5.

Targeting CD20+ Aggressive B-cell Non-Hodgkin Lymphoma by Anti-CD20 CAR mRNA-Modified Expanded Natural Killer Cells In Vitro and in NSG Mice.

Chu Y, Hochberg J, Yahr A, Ayello J, van de Ven C, Barth M, Czuczman M, Cairo MS.

Cancer Immunol Res. 2014 Dec 9. [Epub ahead of print]

PMID:
25492700
[PubMed - as supplied by publisher]
6.

Radiation for diffuse large B-cell lymphoma in the rituximab era: Analysis of the National Comprehensive Cancer Network lymphoma outcomes project.

Dabaja BS, Vanderplas AM, Crosby-Thompson AL, Abel GA, Czuczman MS, Friedberg JW, Gordon LI, Kaminski M, Niland J, Millenson M, Nademanee AP, Zelenetz A, LaCasce AS, Rodriguez MA.

Cancer. 2014 Dec 9. doi: 10.1002/cncr.29113. [Epub ahead of print]

PMID:
25492236
[PubMed - as supplied by publisher]
7.

18F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study.

Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppä S, Jyrkkiö S, Holte H, Eriksson M, Gillstrøm D, Hansen PB, Seppänen M, Hjorthaug K, Brown PD, Pedersen LM.

Leuk Lymphoma. 2014 Nov 20:1-8. [Epub ahead of print]

PMID:
25330442
[PubMed - as supplied by publisher]
8.

The Diaphanous-Related Formins Promote Protrusion Formation and Cell-to-Cell Spread of Listeria monocytogenes.

Fattouh R, Kwon H, Czuczman MA, Copeland JW, Pelletier L, Quinlan ME, Muise AM, Higgins DE, Brumell JH.

J Infect Dis. 2014 Oct 3. pii: jiu546. [Epub ahead of print]

PMID:
25281757
[PubMed - as supplied by publisher]
9.

Non-Hodgkin's lymphomas, version 4.2014.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Saad AA, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2014 Sep;12(9):1282-303.

PMID:
25190696
[PubMed - in process]
10.

In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma.

Hutchings M, Kostakoglu L, Zaucha JM, Malkowski B, Biggi A, Danielewicz I, Loft A, Specht L, Lamonica D, Czuczman MS, Nanni C, Zinzani PL, Diehl L, Stern R, Coleman M.

J Clin Oncol. 2014 Sep 1;32(25):2705-11. doi: 10.1200/JCO.2013.53.2838. Epub 2014 Jul 28.

PMID:
25071108
[PubMed - indexed for MEDLINE]
11.

Follicular lymphoma grade 3: review and updates.

Vaidyanathan G, Czuczman MS.

Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):431-5. doi: 10.1016/j.clml.2014.04.008. Epub 2014 Jun 12.

PMID:
25066038
[PubMed - in process]
12.

CALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.

Du J, Lopez-Verges S, Pitcher BN, Johnson J, Jung SH, Zhou L, Hsu K, Czuczman MS, Cheson B, Kaplan L, Lanier LL, Venstrom JM.

Cancer Immunol Res. 2014 Sep;2(9):878-89. doi: 10.1158/2326-6066.CIR-13-0158. Epub 2014 Jun 23.

PMID:
24958280
[PubMed - in process]
13.

Non-Hodgkin's lymphomas, version 2.2014.

Zelenetz AD, Gordon LI, Wierda WG, Abramson JS, Advani RH, Andreadis CB, Bartlett N, Bellam N, Byrd JC, Czuczman MS, Fayad LE, Fisher RI, Glenn MJ, Harris NL, Hoppe RT, Horwitz SM, Kelsey CR, Kim YH, Krivacic S, LaCasce AS, Nademanee A, Porcu P, Press O, Rabinovitch R, Reddy N, Reid E, Sokol L, Swinnen LJ, Tsien C, Vose JM, Yahalom J, Zafar N, Dwyer M, Sundar H.

J Natl Compr Canc Netw. 2014 Jun;12(6):916-46.

PMID:
24925202
[PubMed - indexed for MEDLINE]
14.

Integrating emerging treatment options in mantle cell lymphoma.

Kahl BS, Fowler NH, Czuczman MS.

Clin Adv Hematol Oncol. 2013 Dec;11(12 Suppl 19):1-15. Review.

PMID:
24893155
[PubMed - indexed for MEDLINE]
15.

Listeria monocytogenes exploits efferocytosis to promote cell-to-cell spread.

Czuczman MA, Fattouh R, van Rijn JM, Canadien V, Osborne S, Muise AM, Kuchroo VK, Higgins DE, Brumell JH.

Nature. 2014 May 8;509(7499):230-4. doi: 10.1038/nature13168. Epub 2014 Apr 13.

PMID:
24739967
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network.

Herrera AF, Crosby-Thompson A, Friedberg JW, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Millenson MM, Nademanee AP, Niland JC, Rodig SJ, Rodriguez MA, Zelenetz AD, LaCasce AS.

Cancer. 2014 Jul 1;120(13):1993-9. doi: 10.1002/cncr.28676. Epub 2014 Apr 4.

PMID:
24706502
[PubMed - indexed for MEDLINE]
17.

Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia.

Barth MJ, Czuczman MS.

Future Oncol. 2013 Dec;9(12):1829-39. doi: 10.2217/fon.13.219.

PMID:
24295413
[PubMed - indexed for MEDLINE]
18.

An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

Zhou Z, Sehn LH, Rademaker AW, Gordon LI, Lacasce AS, Crosby-Thompson A, Vanderplas A, Zelenetz AD, Abel GA, Rodriguez MA, Nademanee A, Kaminski MS, Czuczman MS, Millenson M, Niland J, Gascoyne RD, Connors JM, Friedberg JW, Winter JN.

Blood. 2014 Feb 6;123(6):837-42. doi: 10.1182/blood-2013-09-524108. Epub 2013 Nov 21.

PMID:
24264230
[PubMed - indexed for MEDLINE]
Free Article
19.

A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab.

Press OW, Unger JM, Rimsza LM, Friedberg JW, LeBlanc M, Czuczman MS, Kaminski M, Braziel RM, Spier C, Gopal AK, Maloney DG, Cheson BD, Dakhil SR, Miller TP, Fisher RI.

Clin Cancer Res. 2013 Dec 1;19(23):6624-32. doi: 10.1158/1078-0432.CCR-13-1120. Epub 2013 Oct 15.

PMID:
24130072
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.

Ban-Hoefen M, Vanderplas A, Crosby-Thompson AL, Abel GA, Czuczman MS, Gordon LI, Kaminski MS, Kelly J, Millenson M, Nademanee AP, Rodriguez MA, Zelenetz AD, Niland J, LaCasce AS, Friedberg JW.

Br J Haematol. 2013 Nov;163(4):487-95. doi: 10.1111/bjh.12570. Epub 2013 Sep 20.

PMID:
24111533
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk